Search through
Desvenlafaxine Succinate is a serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant used to treat major depressive disorder (MDD) in adults. It is the active metabolite of venlafaxine, another antidepressant, and works by increasing the levels of serotonin and norepinephrine in the brain, which helps regulate mood. It is a metabolite of the drug venlafaxine. It has a role as a marine xenobiotic metabolite, a drug metabolite and an antidepressant. This api is EU approved in Spain (2012) and Germany (2022). Also (FDA) Approved for major depressive disorder in adults.
Desvenlafaxine Succinate is a serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant used to treat major depressive disorder (MDD) in adults. It is the active metabolite of venlafaxine, another antidepressant, and works by increasing the levels of serotonin and norepinephrine in the brain, which helps regulate mood. It is a metabolite of the drug venlafaxine. It has a role as a marine xenobiotic metabolite, a drug metabolite and an antidepressant. This api is EU approved in Spain (2012) and Germany (2022). Also (FDA) Approved for major depressive disorder in adults.
.3d8f8f41.svg)
Pharmaceutical
.3556d45a.svg)
Pharmaceutical Actives & Precursors
Active Pharmaceutical Ingredients (APIs)
.7767eb0f.png)
Chemical Properties & Specifications
H315: Causes skin irritation. H319: Causes serious eye irritation. H335: May cause respiratory irritation.
P261: Avoid breathing dust/fume/gas/mist/vapors/spray. P264: Wash hands thoroughly after handling. P271: Use only outdoors or in a well-ventilated area. P280: Wear protective gloves/eye protection/face protection. P302+P352: IF ON SKIN: Wash with plenty of soap and water. P304+P340: IF INHALED: Remove person to fresh air and keep comfortable for breathing. P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P312: Call a POISON CENTER or doctor if you feel unwell. P321: Specific treatment (see on this label). P332+P313: If skin irritation occurs: Get medical advice/attention. P337+P313: If eye irritation persists: Get medical advice/attention. P362: Take off contaminated clothing and wash before reuse. P403+P233: Store in a well-ventilated place. Keep container tightly closed. P405: Store locked up. P501: Dispose of contents/container in accordance with local/regional/national/international regulations.
Desvenlafaxine Succinate is prescribed for the treatment of MDD in adults. It helps alleviate symptoms such as persistent feelings of sadness, loss of interest in daily activities, and fatigue.
Incorporated into oral dosage forms, specifically extended-release tablets, to ensure consistent delivery of the medication over time. Common strengths include 25 mg, 50 mg, and 100 mg tablets.
Store in a cool, dry place, away from incompatible substances. Keep container tightly closed when not in use.
Available in various sizes, including 25 mg, 50 mg, and 100 mg vials, suitable for both research and pharmaceutical applications.
Desvenlafaxine Succinate is primarily used to treat major depressive disorder (MDD) in adults by increasing the levels of serotonin and norepinephrine in the brain, which helps regulate mood.
It is typically taken once daily, with or without food. The tablets should be swallowed whole and not divided, crushed, chewed, or dissolved.
Common side effects include nausea, dizziness, and dry mouth. Serious side effects may include increased blood pressure, suicidal thoughts, and serotonin syndrome. Always consult your healthcare provider if you experience any unusual symptoms. Sexual dysfunction: Including decreased libido and difficulty achieving orgasm.
Desvenlafaxine Succinate is a serotonin-norepinephrine reuptake inhibitor (SNRI) that works by inhibiting the reuptake of serotonin and norepinephrine in the brain, thus increasing their concentrations and helping to regulate mood.
Desvenlafaxine Succinate is approved by regulatory bodies such as the FDA for major depressive disorder in adults. It complies with cGMP standards for pharmaceutical manufacturing and is supported by DMF submissions for global markets.
